UY33376A - Sal de tipo hemifumarato - Google Patents
Sal de tipo hemifumaratoInfo
- Publication number
- UY33376A UY33376A UY0001033376A UY33376A UY33376A UY 33376 A UY33376 A UY 33376A UY 0001033376 A UY0001033376 A UY 0001033376A UY 33376 A UY33376 A UY 33376A UY 33376 A UY33376 A UY 33376A
- Authority
- UY
- Uruguay
- Prior art keywords
- hemifumarate
- type salt
- relates
- present
- salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/50—Ketonic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a una sal de tipo hemifumarato del compuesto (1S)-1-(2-(difluorometil)piridin-4-il)-4-fluoro-1-(3-(pirimidin-5-il)fenil)-1H-isoindol-3-amina, a la Forma A de esta y a sus composiciones farmacéuticas. Además, la presente invención se refiere a métodos terapéuticos para el tratamiento y/o la prevención de patologías relacionadas con Aß tal como la enfermedad de Alzheimer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33388310P | 2010-05-12 | 2010-05-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY33376A true UY33376A (es) | 2011-12-30 |
Family
ID=44912284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001033376A UY33376A (es) | 2010-05-12 | 2011-05-11 | Sal de tipo hemifumarato |
Country Status (5)
Country | Link |
---|---|
US (1) | US20110281894A1 (es) |
AR (1) | AR081389A1 (es) |
TW (1) | TW201144295A (es) |
UY (1) | UY33376A (es) |
WO (1) | WO2011142716A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8557826B2 (en) | 2009-10-08 | 2013-10-15 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use |
EP2485591B1 (en) | 2009-10-08 | 2016-03-23 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
WO2011044185A2 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
JP2014514302A (ja) | 2011-04-13 | 2014-06-19 | メルク・シャープ・アンド・ドーム・コーポレーション | Bace阻害薬としての5−置換されたイミノチアジン類およびそれのモノおよびジオキシド、組成物およびそれらの使用 |
WO2014099794A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | C5, c6 oxacyclic-fused iminothiazine dioxide compounds as bace inhibitors |
CN108226319A (zh) * | 2016-12-22 | 2018-06-29 | 亚宝药业集团股份有限公司 | 一种检测卡巴拉汀贴剂中光学异构体的方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200815349A (en) * | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
TW201020244A (en) * | 2008-11-14 | 2010-06-01 | Astrazeneca Ab | New compounds |
-
2011
- 2011-05-11 WO PCT/SE2011/050592 patent/WO2011142716A1/en active Application Filing
- 2011-05-11 US US13/105,569 patent/US20110281894A1/en not_active Abandoned
- 2011-05-11 UY UY0001033376A patent/UY33376A/es not_active Application Discontinuation
- 2011-05-11 TW TW100116563A patent/TW201144295A/zh unknown
- 2011-05-11 AR ARP110101624A patent/AR081389A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2011142716A1 (en) | 2011-11-17 |
AR081389A1 (es) | 2012-08-29 |
TW201144295A (en) | 2011-12-16 |
US20110281894A1 (en) | 2011-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY33376A (es) | Sal de tipo hemifumarato | |
HRP20182069T1 (hr) | Farmaceutski pripravci za liječenje alzheimerove bolesti | |
CR20150078A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
UA115122C2 (uk) | Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським | |
MX2015008957A (es) | Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1). | |
MX2020003112A (es) | Composiciones de biguanida y metodos para tratar trastornos metabolicos. | |
EP2576540A4 (en) | HETEROARYLATED COMPOUNDS AND METHODS OF USE | |
CR20130377A (es) | Métodos y productos de fármaco para tratar enfermedad de alzheimer | |
HK1174330A1 (en) | Ppar-sparing thiazolidinedione salts for the treatment of metabolic diseases ppar- | |
PH12015502365A1 (en) | Bace1 inhibitors | |
MX356728B (es) | Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2. | |
MX349224B (es) | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa. | |
ZA201401678B (en) | Novel distributed 3,4-diamino-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | |
ZA201402907B (en) | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies | |
IT1391866B1 (it) | Composizione iniettabile di polinucleotidi per il trattamento di patologie osteoarticolari. | |
MY167898A (en) | Co-crystals and salts of ccr3-inhibitors | |
BRPI1013245A2 (pt) | "composto para o tratamento de distúrbios metabólicos" | |
MX2013011124A (es) | Compuestos para el tratamiento del sindrome metabolico. | |
EP2398789A4 (en) | SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
PE20160009A1 (es) | 4-(5-(4-clorofenil)-2-(2-ciclopropilacetil)-1,4-dimetil-1h-pirrol-3-il)bencenosulfonamida como modulador de nachr alfa 7 | |
NZ702239A (en) | Heteroaryl compounds and methods of use thereof | |
MX2016008968A (es) | Compuestos organicos. | |
PH12017501955A1 (en) | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease | |
BR112016029604A2 (pt) | ?sais farmaceuticamente aceitáveis, forma cristalina, padrão cristalino, composições farmacêuticas, sais de glucamina, utilização de um sal e de uma composição farmacêutica, método para o tratamento do câncer e composto para a utilização? | |
MX365292B (es) | 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
104 | Application deemed to be withdrawn (no substantive examination fee paid) |
Effective date: 20130805 |